Gastrointestinal Stromal Tumors (GIST)
Oncology·MeSH: Gastrointestinal Stromal Tumors
Prevalence
30.0 / 100K
1 drug in development·1 company·0 clinical trials
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| THE-630 | Theseus Pharmaceuticals, Inc. (THRX) |
Frequently asked questions
How many drugs are in development for Gastrointestinal Stromal Tumors (GIST)?
BioSniper tracks 1 drug in development for Gastrointestinal Stromal Tumors (GIST) across 1 company.
What is the prevalence of Gastrointestinal Stromal Tumors (GIST)?
The estimated prevalence of Gastrointestinal Stromal Tumors (GIST) is approximately 30.0 per 100,000 population.
Deep-dive into Gastrointestinal Stromal Tumors (GIST)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis